“2023 brought many uncertainties to the pharma sector in China,” a Jan. 10 article in Pink Sheet titled “China Regulation in Year Of The Dragon: Good Distribution Practice, Corporate Law, Export Bans” outlined. “As we move to the year of the dragon in the 12-year Chinese zodiac cycle, the outlook is for multiple further changes in the country's biopharma policy and regulatory environment,” the piece continued. Singapore life sciences partner Katherine Wang was cited throughout the article on an array of regulatory developments impacting China’s biopharma industry.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.